Abstract:The key of individualized therapy is that using molecular markers to select more suitable drug. At present, some studies have confirmed that certain molecular markers can predict the efficacy of the drugs. For example, cetuximab is beneficial in patients with K-ras wildtype colorectal cancer, gefitinib and erlotinib are beneficial in patients with epidermal growth factor receptor（EGFR） mutationpositive nonsmall cell lung cancer(NSCLC), imatinib is beneficial in patients with C-KIT genepositive gastrointestinal stromal tumor. In terms of safety, the promoter polymorphism of UDP glucuronosyltransferase 1 polypeptide A1(UGT1A1) can predict the toxicity of irinotecan.

Key words:Biological markers,Genes,Mutation,Gene expression